Τόμος 32 (2014) – Τεύχος 2 – Άρθρο 6 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 32 (2014) – Issue 2 – Article 6 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Από | | Άρθρο επισκόπησης - Review Article, Ιωάννα Γκρεκ - Ioanna Grech, Πλήρες Κείμενο στα Ελληνικά - Full Text in Greek

Τίτλος – Title
Εμμηνόπαυση και Παχυσαρκία
Menopause and Obesity
Συγγραφέας – Author

Ιωάννα Γκρεκ MSc, PhD
Eπίκουρη Καθηγήτρια Αισθητικής και Κοσµητολογίας, ∆ιδάκτωρ Ιατρικής Σχολής Πανεπιστηµίου Αθηνών, Τµήµα Αισθητικής και Κοσµητολογίας, Σχολή Επαγγελµάτων Υγείας και Πρόνοιας, Τεχνολογικό Ίδρυµα Αθηνών, Αθήνα, Ελλάς –
Ioanna Grech
Department of Aesthetics and Cosmetology, School of Professions of Health and Welfare, Technological Educational Institution of Athens, Egaleo, Athens, Hellas

Παραπομπή – Citation

Γκρεκ Ι.: Εμμηνόπαυση και Παχυσαρκία, Επιθεώρηση Κλιν. Φαρμακολ. Φαρμακοκινητ. 32: 113-117 (2014)
Grech I.: Menopause and Obesity, Epitheorese Klin. Farmakol. Farmakokinet. 32: 113-117 (2014)
Ημερομηνία Δημοσιευσης – Publication Date
13 Ιουνίου 2014 – 2014-06-13
Γλώσσα Πλήρους Κειμένου – Full Text Language
Ελληνικά – Greek
Λέξεις κλειδιά – Keywords

Παχυσαρκία, εμμηνόπαυση, σύνδρομο μεταβολισμού, διαβήτης τύπου ΙΙ, γενετικοί παράγοντες, καρκίνος του μαστού
Obesity, menopause, metabolic syndrome, diabetes mellitus type II, genetic factors, breast cancer
Λοιποί Όροι – Other Terms

άρθρο επισκόπησης, , , , , , , , , , , , , , , ,  ,
review article, , , , , , , , , , , ,

Περίληψη – Summary

Η εμφάνιση της παχυσαρκίας κατά τη διάρκεια της εμμηνόπαυσης είναι ένα φαινόμενο που οφείλεται στη διαφοροποίηση και επικράτηση των ανδρογόνων έναντι των οιστρογόνων. Η παχυσαρκία αυτή συμβάλλει στην ανάπτυξη του μεταβολικού συνδρόμου που σχετίζεται με την αντοχή στην ινσουλίνη, την ανάπτυξη σακχαρώδους διαβήτη τύπου ΙΙ, την εμφάνιση καρδιαγγειακών παθήσεων και του καρκίνου με έκδηλο παράδειγμα τον καρκίνο του μαστού. Η διερεύνηση γενετικών παραγόντων ενοχοποιεί κάποια συγκεκριμένα γονίδια που συντελούν στην ομαλή λειτουργία του Νευρικού Συστήματος, αλλά και στην ομοιόσταση του οργανισμού. Το παράδειγμα του καρκίνου του μαστού σε σχέση με την παχυσαρκία στην εμμηνόπαυση δηλώνει την απαραίτητη παρουσία των οιστρογόνων για την αποφυγή του καρκίνου. Η εμφάνιση της παχυσαρκίας στην περίοδο της εμμηνόπαυσης είναι ένας ιδιαίτερα επιβαρυντικός παράγων.
The establishment of obesity during menopause is a clinical phenomenon which is due primarily, to the differentiation and sustaining of androgens over estrogens. This type of obesity contributes the most to the establishment of metabolic syndrome. Metabolic syndrome is related to the diabetes mellitus type II, to the cardiovascular diseases and to cancer, with the most prominent example that of breast cancer. The investigation of some genetic factors leads to certain genes that orchestrate the homeostasis of the human organism, specifically that of nervous system. The paradigm of breast cancer states the necessary presence of estrogens so to avoid this type of cancer. The occurrence of obesity during menopause is an important contributing factor to disease in this group of population.
Αναφορές – References
 1. Poehlman E.T., Toth M.J., Gardner A.W.: Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern. Med. 123: 673-675 (1995)
2. Motala A.A., Esterhuizen T., Pirie F.J., Omar M.A.: The prevalence of metabolic syndrome and determination of the optimal waist circumference cutoff points in a rural South african community. Diabetes Care 34: 1032-1037(2011)
3. Messina G., Vigianno A., De Luca V., Messina A., Chieffi S., Monda M.: Hormonal change in menopause and Orexin-a action. Obstet. Gynecol. Int. (2013) doi:
10.1155/2013/209812. Epub 2013 Jun 11.
4. Anderson E.J., Lavoie H.B., Strauss C.C., Hubbard J.L., Sharpless J.L., Hall J.E.: Body composition and energy balance: lack of effect of short-term hormone replacement in postmenopausal women. Metabolism 50:265-269 (2001)
5. Hjelmborg J.B., Fagnani C., Silventoinen K., McGue M., Korkeila M., Christensen K., Rissanen A., Kaprio J.: Genetic influences on growth traits of BMI: a longitudinal study of adult twins. Obesity 16: 847-852 (2008)
6. Wardle J., Carnell S., Haworth C.M., Plomin R.: Evidence for a strong genetic influence on childhood adiposity despite the force of the odesogenic environment. Am. J. Clin. Nutr. 87: 398-404. (2008).
7. Potischman N., Swanson S.A., Siiteri P., Hoover R.N.: Reversal of relation between body mass and endogenous eostrogen concentrations with menopausal status. J. Natl. Cancer Inst. 88: 756-758 (1996)
8. La Vecchia C, Negri E, Franceschi S., Talamini R., Bruzzi P., Palli D., Decarli A.: Body mass index and postmenopausal breast cancer. An age specific analysis. Br J. Cancer. 75: 441-444 (1997)
9. Franceschi S., Favero A., Barón A.E., Negri E., Dal Maso L., Giacosa A., Montella M., Conti E., Amadori D.: Body size indices and breast cancer risk before and after menopause. Int. J. Cancer 67: 181-186 (1996)
10. Suba Z.: Circulatory oestrogen level protects against breast cancer in obese women. Recent Pat Anti-cancer Drug Discov. 8: 154-167 (2013).
11. Reaven G.M.: Insulin resistance cardiovascular disease and the metabolic syndrome: How do the emperors clothes fit? Diabetes Care 27: 1011-1012 (2004)
12. Gu D., Reynolds K., Wu X., Chen J., Duan X., Reynolds R.F., Whelton P.K., He J.; InterASIA Collaborative Group.: Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365: 1398-1405 (2005)
13. Ding Q.F., Hayashi T., Zhang X.J., Funami J., Ge L., Li J., Huang X.L., Cao L., Zhang J., Akihisa I.: Risks of CHD identified by different criteria of metabolic syndrome and related changes of adipocytokines in elderly postmenopausal women. J. Diabetes Complications 21: 315-319 (2007)
14. Kim H.M., Park J., Ryu S.Y., Kim J.: The effect of menopause on the metabolic syndrome among Korean women: the Korean National Health and Nutrition Examination Survey, 2001. Diabetes Care 30: 701-706 (2007)
15. Cho G.J., Lee J.H., Park H.T., Shin J.H., Hong S.C., Cho G.J., Lee J.H., Park H.T., Shin J.H., Hong S.C.: Postmenopausal status according to years since meno-pause as an independent risk factor for the metabolic syndrome. Menopause 15: 524-529 (2008)
16. Ruan X., Jin J., Hua L., Liu Y., Wang J., Liu S.: The prevalence of metabolic syndrome in Chinese postmenopausal women and the optimum body composition indices to predict it. Menopause 17: 566-70 (2010)
17. Anderson E.J., Lavoie H.B., Strauss C.C., Hubbard J.L., Sharpless J.L., Hall J.E.: Body composition and energy balance: lack of effect of short-term hormone replacement in postmenopausal women. Metabolism 50: 265-
269 (2001)
18. Reubinoff B.E., Wurtman J., Rojansky N., Adler D., Stein P., Schenker J.G., Brzezinski A.: Effects of hormone replacement therapy on weight, body com-position, fat distribution, and food intake in early post-menopausal women: a prospective study. Fertil. Steril. 64: 963-968
(1995)
19. Espeland M.A., Stefanick M.L., Kritz-Silverstein D., Fineberg S.E., Waclawiw M.A., James M.K., Greendale G.A.: Effect of postmenopausal hormone therapy on body
weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. J. Clin. Endocrinol. Metab. 82: 1549-1556 (1997)
20. O’Sullivan A.J., Hoffman D.M., Ho K.K.: Estrogen, lipid oxidation, and body fat. N. Engl. J. Med. 333: 669-670 (1995)
21. O’Sullivan A.J., Crampton L.J., Freund J., Ho K.K.Y.: The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J. Clin. Invest. 102: 1035-1040 (1998)
22, Wade G.N., Gray J.M.: Gonadal effects on food intake and adiposity: a metabolic hypothesis. Physiol. Behav. 22: 583-593 (1979)
23. Dagnault A., Ouerghi D., Richard D.: Treatment with alpha-helical-CRF(9-41) prevents the anorectic effect of 17-beta-estradiol. Brain Res. Bull. 32: 689-692 (1993)
24. Baghaei F., Rosmond R., Westberg L., Hellstrand M., Eriksson E., Holm G., Björntorp P.: The CYP 19 gene and association with androgens and abdominal obesity in premenopausal women. Obes. Res. 11: 578-575 (2003)
25. Vona-Davis I., McNatt H., Rose D.P.: Adipose type-2 diabetes and the metabolic syndrome in breast cancer. Obes. Res. 8: 395-408 (2007)
26. Yanes L.L., Rechelhoff J.F.: Postmenopausal hypertension. Am. J. Hypertens. 24: 740-749 (2011)
27. Dantas A.P., Tostes R.C., Fortes Z.B., Costa S.G., Nigro D., Carvalho M.H.: In vivo evidence for antioxidant potential of estrogen in microvessels of female spontaneously hypertensive rats. Hypertension 39: 405-411 (2002)
28. Viña J., Sastre J, Pallardó F.V, Gambini J, Borrás C.: Role of the mitochondrial oxidative stress to explain the different longevity between genders: protective effect of ostrogens. Free Radic. Res. 40: 1359-1365 (2006)
29. Tiano J.P., Mauvais-Jarvis F.: Importance of eotrogen receptors to preserve functional β-cell mass in diabetes. Nat. Rev. Endocrinol. 8: 342-351 (2012)
30. Maes H.H., Neale M.C., Eaves L.J.: Genetic and environmental factors in relative body weight and human adiposity. Behav. Genet. 27: 325-351 (1997)
31. Thorleifsson G., Walters G.B., Gudbjartsson D.F., Steinthorsdottir V., Sulem P., Helgadottir A., Styrkarsdottir U., Gretarsdottir S., Thorlacius S., Jonsdottir I., Jonsdottir T., Olafsdottir E.J., Olafsdottir G.H., Jonsson T., Jonsson
F., Borch-Johnsen K., Hansen T., Andersen G., Jorgensen T., Lauritzen T., Aben K.K., Verbeek A.L., Roeleveld N., Kampman E., Yanek L.R., Becker L.C., Tryggvadottir L., Rafnar T., Becker D.M., Gulcher J., Kiemeney L.A., Pedersen
O., Kong A., Thorsteinsdottir U., Stefansson K.: Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat. Genet. 41:18-24 (2009)
32. Murchison E.P., Hannon G.J.: miRNAs on the move: miRNA biogenesis and the RNAi machinery. Curr. Opin. Cell. Biol. 16: 223-229 (2004)
33. Wienholds E., Koudijs M.J., van Eeden F.J., Cuppen E., Plasterk R.H.: The microRNAproducing enzyme Dicer1 is essential for zebrafish development. Nat. Genet. 35: 217-
218 (2003)
34. Wing M.R., Ziegler J.M., Langefeld C.D., Roh B.H., Palmer N.D., Mayer-Davis E.J., Rewers M.J., Haffner S.M., Wagenknecht L.E., Bowden D.W.: Analysis of FTO gene variants with obesity and glucose homeostasis measures in the multiethnic Insulin Resistance Atherosclerosis Study cohort. Int. J. Obes. (Lond.) 35: 1173-1182 (2011)
35. Velez Edwards D.R., Naj A.C., Monda K., North K.E., Neuhouser M., Magvanjav O., Kusimo I., Vitolins M.Z., Manson J.E., O’Sullivan M.J., Rampersaud E., Edwards T.L.: Gene-environment interactions and obesity traits among postmenopausal African-American and Hispanic
women in the Women’s Health Initiative SHARe Study. Hum. Genet. 132: 323-336 (2013)
36. Rosato V., Bosetti C., Talamini R., Levi F., Negri E., La Vecchia C.: Metabolic syndrome and the risk of breast cancer. Recenti. Prog. Med. 102: 476-478 (2011) 37. Heemskerk VH., Daemen MA., Buurman W.A.: Insulin like growth factor -1 (IGF-1) and growth hormone (GH) in
immunity and inflammation. Cytokine Growth Factor Rev. 10(1): 5-14 (1999)
38. Fantuzzi G.: Adipose tissue adipokines and inflammation. J. Allerg. Clin. Immunol. 115: 911-919 (2005)
39. Cirillo D., Rachiglio A.M.: Leptinsignalling in breast cancer. An overview. J. Cell. Biochem. 105: 956-964 (2008)
40. Scaffler A., Scölmerich J., Buechler C.: Mechanisms of disease. Adipokines and breast cancer-endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat. Clin. Pract. Endocrinol. Metab. 3: 345-354 (2007)
41. Grossman M.E., Cleary M.P.: The balance between leptin and adiponectin in the control of carcinogenesisfocus on mammary tumourigenesis. Biochimie 94: 2164-2171 (2007)
42. den Hollander P., Savage M.I., Brown P.H.: TargetedTherapy for Breast Cancer Prevention. Front. Oncol. 3: 250
(2013)
Σχετικές Εργασίες – Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor

Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση Articles Published in Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ – ANNUAL SUBSCRIPTION
Γλώσσα Πλήρους Κειμένου – Full Text Language
Ελληνικά – Greek
Παραγγελία – Αγορά – Order – Buy
pharmakonpress[at]pharmakonpress[.]gr
pharmakonpress[at]pharmakonpress[.]gr
Προσθέστε στους σελιδοδείκτες το μόνιμο σύνδεσμο.

Τα σχόλια είναι απενεργοποιημένα.